Company profile
ACADIA PHARMACEUTICALS INC
NASDAQ:ACADBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PIMAVANSERIN TARTRATE | approved | — | 8 | approved |
| Trofinetide | approved | — | 4 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (39)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03575052 | phase3 | completed | 2018-05-21 | 2022-05-06 | ACADIA Pharmaceuticals Inc. | A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease |
| NCT03118947 | phase2 | completed | 2017-02-23 | 2019-02-25 | ACADIA Pharmaceuticals Inc. | A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease |
| NCT00658567 | phase3 | completed | 2008-03-01 | 2009-12-01 | ACADIA Pharmaceuticals Inc. | A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis |
| NCT00477672 | phase3 | completed | 2007-06-01 | 2009-06-01 | ACADIA Pharmaceuticals Inc. | A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis |
| NCT02035553 | phase2 | completed | 2013-11-01 | 2016-09-28 | ACADIA Pharmaceuticals Inc. | A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis |
FDA applications (4)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 207318 | NDA | ACADIA PHARMACEUTICALS INC | ||||
Loading… | ||||||
| NDA 210793 | NDA | ACADIA PHARMACEUTICALS INC | ||||
Loading… | ||||||
| NDA 217026 | NDA | ACADIA PHARMACEUTICALS INC | ||||
Loading… | ||||||
| NDA 219884 | NDA | ACADIA PHARMACEUTICALS INC | ||||
Loading… | ||||||